Comparing three treatments for low-risk MDS with anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests three different treatments for people with a type of bone marrow disorder called low-risk myelodysplastic syndrome (MDS) that causes low red blood cells (anemia). The goal is to see which treatment works best and to find out more about the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been accepted into the main MyeloMATCH screening study first.
- You have been diagnosed with low-risk MDS (IPSS-R score of 3.5 or lower) and have anemia that causes symptoms like tiredness or shortness of breath.
- You are 18 years or older.
- You have not had any prior treatment for MDS (like luspatercept, lenalidomide, or chemotherapy). You may have had up to 2 doses of erythropoietin (a drug to boost red blood cells) if it was more than 8 weeks ago.
- Your blood counts and kidney/liver function meet specific levels, and your erythropoietin level is 500 IU/L or less.
- You do not have MDS with a specific chromosome change (del5q), and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial tests how well a biosimilar version of erythropoietin (a drug that boosts red blood cells) works in people with low-risk myelodysplastic syndrome (MDS) who have anemia. It aims to see if this treatment can safely improve low hemoglobin levels without needing more intensive therapies.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
Hear when a new Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.